VolitionRX Ltd. (VNRX)

4.47
0.22 5.20
AMEX : Health Services
Prev Close 4.25
Open 4.26
Day Low/High 4.26 / 4.42
52 Wk Low/High 1.67 / 4.65
Volume 33.61K
Avg Volume 116.50K
Exchange AMEX
Shares Outstanding 41.09M
Market Cap 175.04M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Volition Forms Texas-Based Veterinary Subsidiary And Appoints Its Chief Executive Officer

Volition Forms Texas-Based Veterinary Subsidiary And Appoints Its Chief Executive Officer

AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal...

VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call And Business Update

VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call And Business Update

Conference call to take place Tuesday, August 13, 2019 at 8:30 am Eastern time

Volition Announces Exercise Of Warrant To Purchase $4.8 Million In Common Stock

Volition Announces Exercise Of Warrant To Purchase $4.8 Million In Common Stock

AUSTIN, Texas, July 24, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a further strengthening of its balance sheet with an existing investor exercising the balance of its warrant to purchase $4.

VolitionRx Limited Commences Lung Cancer Clinical Study With Fosun Long March In China

VolitionRx Limited Commences Lung Cancer Clinical Study With Fosun Long March In China

AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co.

VolitionRx Limited Awarded An Additional $1.4 Million In Non-Dilutive Funding

VolitionRx Limited Awarded An Additional $1.4 Million In Non-Dilutive Funding

AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.

VolitionRx Limited Announces First Quarter 2019 Financial Results And Business Update

VolitionRx Limited Announces First Quarter 2019 Financial Results And Business Update

Conference call to discuss financial and operational results scheduled for Thursday, May 9 at 8:30 a.m. U.S. Eastern Time

VolitionRx Limited Executes A Contract For Clinical Trial Program In Lung Cancer

VolitionRx Limited Executes A Contract For Clinical Trial Program In Lung Cancer

AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of...

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call And Business Update

VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call And Business Update

Conference call to take place Thursday, May 9, 2019 at 8:30 am Eastern time

VolitionRx Limited Hosts Capital Markets Day At The New York Stock Exchange And Issues Company Update Report

VolitionRx Limited Hosts Capital Markets Day At The New York Stock Exchange And Issues Company Update Report

ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress.

VolitionRx Limited Signs Memorandum Of Understanding With Texas A&M University For Potential Collaboration To Develop Nu.QTM Veterinary Diagnostics

VolitionRx Limited Signs Memorandum Of Understanding With Texas A&M University For Potential Collaboration To Develop Nu.QTM Veterinary Diagnostics

ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a...

VolitionRx Limited Extends Clinical Trial Program In Lung Cancer

VolitionRx Limited Extends Clinical Trial Program In Lung Cancer

ISNES, Belgium, April 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its...

VolitionRx Limited To Present At Conferences In March & April 2019

VolitionRx Limited To Present At Conferences In March & April 2019

ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019.

Health Care Stocks Still Healthy Despite Higher Hedging Costs

Health Care Stocks Still Healthy Despite Higher Hedging Costs

Health care is still outperforming the overall indices -- mergers and stellar sales figures and all. Can it be sustained?